-
How do doctors diagnose non-small cell lung cancer?
31 Jan 2023 14:21 GMT
Non-small cell lung cancer (NSCLC) involves the growth of cancerous … carcinoma.
Individuals experiencing symptoms of NSCLC may first visit a doctor … provide individual recommendations for treating NSCLC.
The most common type of …
-
Early-Stage Non-Small Cell Lung Cancer: Mitigating the Rigors of Therapy
30 Jan 2023 17:47 GMT
Mark Socinski, MD, considers the challenges surrounding the identification of patients with early-stage non–small cell lung cancer who do not require adjuvant therapy.
Citing the respective costs of adjuvant chemotherapy and immunotherapy in terms of …
-
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
30 Jan 2023 13:19 GMT
… or metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 …
“Metastatic non-squamous non-small cell lung cancer remains a challenge because … visit ClinicalTrials.gov.
About Non-Small Cell Lung Cancer Without Actionable Genomic Alterations …
-
Merck gets USFDA nod for KEYTRUDA as adjuvant treatment for non-small cell lung cancer
30 Jan 2023 09:43 GMT
… [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
The approval is based on … immunotherapy treatment option for non-small cell lung cancer patients with stage IB … meaningful advances for patients with non-small cell lung cancer.”
"With this approval …
-
Daiichi Sankyo begins patient dosing in TROPION─Lung07 phase 3 trial to evaluate datopotamab deruxtecan in combo with pembrolizumab to treat patients with previously untreated metastatic NSCLC
31 Jan 2023 13:48 GMT
… or metastatic non-squamous non-small cell lung cancer (NSCLC) with PD-L1 expression … patients.
“Metastatic non-squamous non-small cell lung cancer remains a challenge because … treatment of patients with non-small cell lung cancer, across PD-L1 segments …
-
Long Noncoding RNA LINC01426 Sequesters microRNA-519d-5p to Promote Non-Small Cell Lung Cancer Progression by Increasing ETS1 Expression [Retraction]
28 Jan 2023 01:15 GMT
Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708.
At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article. Following publication of an Expression of concern for their …
-
Stage IIA Node-Negative NSCLC Patients: Outcomes after SBRT Vs. IMRT and 3DCRT
30 Jan 2023 22:19 GMT
… Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm … patients with stage IIA non-small cell lung cancer (NSCLC) tumors more than … (AJCC TNM7) N0 non-small cell lung cancer (NSCLC) more than 5 … treating big, inoperable NSCLC tumors in elderly patients …
-
Merck's KEYTRUDA Gets FDA Approval To Treat Stage IB, II, IIIA Non-small Cell Lung Cancer Patients
27 Jan 2023 12:31 GMT
… centimeters), II, or IIIA non-small cell lung cancer or NSCLC.
With this approval, KEYTRUDA … -line treatment of metastatic non-small cell lung cancer and has changed the … fifth indication for KEYTRUDA in non-small cell lung cancer and the first indication …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
The approval is based on … immunotherapy treatment option for non-small cell lung cancer patients with stage IB … of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
The approval is based on … immunotherapy treatment option for non-small cell lung cancer patients with stage IB … of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or …